NasdaqGM:RLAYBiotechs
Relay Therapeutics (RLAY) Q1 Loss Of US$73.3 Million Tests Growth At A Loss Narrative
Relay Therapeutics (RLAY) opened 2026 with Q1 revenue of US$3 million, basic EPS of a US$0.41 loss, and a net loss excluding extra items of US$73.3 million, setting a clear snapshot of where the business is starting the year. The company has seen quarterly revenue move between US$0 and US$7.7 million since early 2024, while basic EPS has ranged from a US$0.32 loss to a US$0.46 loss over the same period, giving investors a consistent view of a revenue generating but loss making biotech with...